dpp 4 inhibitors glp 1 GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes Dipeptidyl Peptidase (DPP)-IV Inhibitors with

People with deeper skin tones may notice a gradual brightening effect and reduced pigmentation spots, but their natural skin tone will remain

48 FilomeniG.CirioloM

The companys own announcement states plainly that the FDA is expected to review the CagriSema application in 2026 [4]

If irritation persists, discontinue use and consult with a healthcare professional

Until Phase II and III results emerge with proper endpoints (mucosal healing rates, histologic remission, patient-reported outcomes), the evidence base will remain preclinical

The fatigue associated with GLP-1 compounds appeared in retatrutide trials as well, likely related to reduced caloric intake during the adaptation phase